Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
acknowledged, AIG, amifampridine, Amneal, answer, antidilutive, Arab, Arabia, ATM, Auro, awaiting, Becerra, Benelux, Berkshire, bilateral, bona, Brazil, broken, buyer, campaign, Catalyst, category, CDOR, CFO, CFR, Chair, charter, Chile, China, CISA, CISM, CISO, CISSP, cocktail, comfortable, consecutive, conserved, consignment, CRISC, cure, cutoff, Dayal, deeply, digital, divest, divestiture, Eastern, Egypt, Eleventh, ERA, ERM, erred, Estonia, EURIBOR, Evercore, exceeded, Excellence, extinguishment, fide, finite, FIRDAPSE, forbear, forbearance, Furniture, Grand, guarantor, guest, GxP, HollisterSteirVetter, IDIQ, imminently, imposter, India, Indivior, inhibit, internship, intranet, Japan, Jubilant, KloxxadoTM, leasehold, Lebanon, lien, literacy, lowest, mAb, macroeconomic, Mar, Marburg, MDEL, misuse, MSSP, multiyear, naloxene, nationwide, newborn, NIST, NOC, notional, objectionable, OECD, Opvee, outlook, oversee, PBE, persuasive, Pillar, PLC, posture, preclinical, prepayment, primate, principle, proactively, proficiency, provincial, Qatar, RBC, realigned, reconciling, red, refresh, reinforcing, renegotiate, reoccur, Resilience, resold, retraining, RiVive, RiViveTM, Russia, Saudi, save, sBLA, scrap, shutdown, Simple, SkillBridge, SOFR, solution, SONIA, sooner, sponsorship, stakeholder, strong, Sudan, SUDV, Sujata, syndicated, syndrome, tabletop, tabular, Taiwan, top, transformation, trivalent, TSA, Turkey, unallocated, unrecorded, VAI, VEEV, vendor, Venezuelan, vision, VRC, web, week, wellbeing, Western, WEVEE, ZimhiTM
Removed:
ACA, Affordability, affordable, Africa, aim, Allergy, Altimmune, anticipation, appeal, Asia, aspiration, Austria, automatic, automatically, bacterial, casualty, cholerae, compelling, Concurrently, confidentiality, consisted, consumption, continuously, costing, Czech, deem, Deferral, dehydration, deploy, diarrhea, differentiated, doubtful, drawn, Dukoral, EMA, enterica, exchangeable, Facilitation, febrile, forma, heading, hedged, illiquidity, impending, incidence, inclusive, indexed, infected, Latin, LIBOR, London, long, Luxembourg, mandate, neutralizing, occasionally, opportunistically, optional, owed, Pasteur, paxvax, pledged, polysaccharide, Portugal, prepay, Presidential, pro, productivity, realizing, reclassify, remained, remote, remotely, removing, rolling, Salmonella, Sanofi, seasoned, secondary, serogroup, serotype, Slovakia, South, Southeast, static, supplementary, Supreme, syringe, template, transitioned, traveling, typhi, Typhim, unmet, unrecoverable, Valneva
Financial report summary
?Competition
Pfizer • Thermo Fisher Scientific • Avid Bioservices • Soligenix • SIGA • Dynavax Technologies • Chimerix • Amphastar Pharmaceuticals • Altimmune • Opiant PharmaceuticalsManagement Discussion
- Total revenues decreased $68.2 million, or 6%, to $1.0 billion in 2023. The decrease was due to a decrease in MCM Products revenue of $132.4 million, Bioservices revenue of $31.4 million and Contracts and Grants revenue of $15.1 million, offset by an increase in Commercial Products revenue of $110.7 million.
- Total segment gross margin decreased $65.4 million, or 17%, to $317.6 million in 2023. Total segment gross margin percentage decreased 5 percentage points to 31%. The decrease was primarily due to a decrease in the MCM Products segment gross margin of $173.7 million, partially offset by increases in the Commercial Products segment gross margin and Bioservices segment gross margin of $60.7 million and $47.6 million, respectively. Total segment gross margin and gross margin percentage excludes contracts and grants revenues because the related costs are R&D expenses.
- See "Segment Results" for an expanded discussion of revenues and gross profit.